MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR
Open accessThe DOI matches its Crossref record.
Abstract
Background: Methylation of the O 6-methylguanine-DNA methyltransferase (MGMT) gene promoter is a favorable prognostic factor in glioblastoma patients. However, reported methylation frequencies vary significantly partly due to lack of consensus in the choice of analytical method. Method: We examined 35 low- and 99 high-grade gliomas using quantitative methylation specific PCR (qMSP) and pyrosequencing. Gene expression level of MGMT was analyzed by RT-PCR. Results: When examined by qMSP, 26% of low-grade and 37% of high-grade gliomas were found to be methylated, whereas 97% of low-grade and 55% of high-grade gliomas were found methylated by pyrosequencing. The average MGMT gene expression level was significantly lower in the group of patients with a methylated promoter independent of method used for methylation detection. Primary glioblastoma patients with a methylated MGMT promoter (as evaluated by both methylation detection methods) had approximately 5 months longer median survival compared to patients with an unmethylated promoter (log-rank test; pyrosequencing P = .02, qMSP P = .06). One third of the analyzed samples had conflicting methylation results when comparing the data from the qMSP and pyrosequencing. The overall survival analysis shows that these patients have an intermediate prognosis between the groups with concordant MGMT promoter methylation results when comparing the two methods. Conclusion: In our opinion, MGMT promoter methylation analysis gives sufficient prognostic information to merit its inclusion in the standard management of patients with high-grade gliomas, and in this study pyrosequencing came across as the better analytical method.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
DNA Methylation Cancer Biomarkers: Translation to the Clinic
Locke, W. J., Guanzon, D., Ma, C., Liew, Y. J., Duesing, K. R., Fung, K. Y. C., & Ross, J. P. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01150 · Cited by 472
Tomar, M. S., Kumar, A., Srivastava, C., & Shrivastava, A. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188616 · Cited by 325
Tirzepatide prevents neurodegeneration through multiple molecular pathways
Fontanella, R. A., Ghosh, P., Pesapane, A., Taktaz, F., Puocci, A., Franzese, M., Feliciano, M. F., Tortorella, G., Scisciola, L., Sommella, E., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04927-z · Cited by 67
Bienkowski, M., Berghoff, A. S., Marosi, C., Wöhrer, A., Heinzl, H., Hainfellner, J. A., & Preusser, M. (2015) · Clinical Neuropathology · doi:10.5414/np300904 · Cited by 57
“Several recent studies show that MGMT pyrosequencing is a robust technique that offers valid, reliable and quick evaluation of the MGMT promoter methylation status from formalin-fixed and paraffin-embedded glioblastoma specimens and is therefore a rational candidate method for clinical purposes [7, 8, 9, 10, 11, 12, 1…”
BackgroundMethodInfluentialGenome-Wide Methylation Analyses in Glioblastoma Multiforme
Lai, R. K., Chen, Y., Guan, X., Nousome, D., Sharma, C., Canoll, P., Bruce, J., Sloan, A. E., Cortes, E., Vonsattel, J.-P., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089376 · Cited by 54
“Seven CpG sites in the promoter region of MGMT were selected based on previous validations, with a Qiagen kit (PM00149702) [30].”
Method
Metadata
- Authors
- Håvik, A. B., Brandal, P., Honne, H., Dahlback, H.-S. S., Scheie, D., Hektoen, M., Meling, T. R., Helseth, E., Heim, S., Lothe, R. A., & Lind, G. E.
- Venue
- Journal of Translational Medicine
- Published
- 2012-03-06
- Volume
- 10
- Issue
- 1
- Pages
- 36-36
- ISSN
- 1479-5876 (ISSN-L)
- OpenAlex
- W2103645386
- Cited by
- 114
- References
- 0
- FWCI
- 4.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. https://app.cochat.ai/papers/10.1186/1479-5876-10-36
- The paper
- Håvik, A. B., Brandal, P., Honne, H., Dahlback, H.-S. S., Scheie, D., Hektoen, M., Meling, T. R., Helseth, E., Heim, S., Lothe, R. A., & Lind, G. E. (2012). MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. Journal of Translational Medicine. https://doi.org/10.1186/1479-5876-10-36
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.